Latest in Therapeutics
Sort by
9 items
-
Viking Therapeutics is more than just a weight-loss stock, and that’s drawing cheers
The biotech’s liver-disease treatment is also viewed as best-in-class, earning it a full slate of buy ratings from analysts.Business - MarketWatch - 2 hours ago -
Sage Therapeutics to end development of key therapy after a third trial failure
It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial as a treatment for mild cognitive impairment and mild dementia in ...Business - MarketWatch - Yesterday -
23andMe cuts 40% of its workforce and discontinues therapeutics division
23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costsHealth - ABC News - November 12 -
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.Business - MarketWatch - November 12 -
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial
The stock, which enjoys the unusual position of having all buy ratings from the 13 analysts offering coverage on FactSet, has been on a tear this year, gaining 270% to date in 2024.Business - MarketWatch - November 4 -
Viking Therapeutics’ stock soars 18% as data on oral weight-loss drug looms
Viking Therapeutics Inc.’s stock soared 18% Thursday, after the biotech, which is developing a weight-loss drug in pill form that has raised high hopes among analysts and investors, posted earnings ...Business - MarketWatch - October 24